Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
The cornerstone of ovarian cancer treatment is Cytoreductive Surgery, commonly known as “debulking.” Unlike many other solid tumors, where surgery is abandoned if the cancer has spread, in ovarian cancer, removing metastatic implants provides a survival benefit. The surgical goal is “Macroscopic Complete Resection” (R0), meaning no visible cancer is left to the naked eye. If R0 is not possible, the goal is “Optimal Cytoreduction,” usually defined as leaving no residual nodules larger than one centimeter.
This surgery is often extensive and complex. It involves a midline laparotomy (large vertical incision) to access the entire abdomen. Procedures performed may include Total Abdominal Hysterectomy (removal of uterus), Bilateral Salpingo-Oophorectomy (removal of ovaries and tubes), and Omentectomy (removal of the fatty apron).
Depending on the spread, the surgeon may also perform bowel resections (removing parts of the intestine), splenectomy (removing the spleen), stripping of the diaphragm peritoneum, and removal of lymph nodes. The patient’s survival is directly correlated with the amount of residual disease; those with no visible disease have the best outcomes, highlighting the importance of being treated by a specialized gynecologic oncologist.
Standard chemotherapy for epithelial ovarian cancer typically involves a combination of two drugs: a platinum agent (Carboplatin or Cisplatin) and a taxane (Paclitaxel). This “doublet” therapy is administered intravenously, usually every three weeks for six cycles. The platinum drug binds to DNA, forming cross-links that prevent cell division, while the taxane disrupts microtubule structures required for cell division.
Another mode of delivery is Intraperitoneal (IP) Chemotherapy. In this protocol, chemotherapy is infused directly into the abdominal cavity through a surgically placed port. This bathes the peritoneal implants in a high concentration of the drug, far higher than what can be achieved through the blood. While studies have shown IP therapy can extend survival, it is more toxic and technically challenging to administer, so it is reserved for select patients with optimally debulked Stage III disease.
Dose-dense regimens, in which Paclitaxel is given weekly rather than every 3 weeks, are also used to improve tolerance and potentially efficacy. Neoadjuvant Chemotherapy (NACT) is used for patients who are not initial candidates for surgery; if the tumor shrinks sufficiently after 3-4 cycles, interval surgery is performed.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a sophisticated therapeutic adjunct used during interval debulking surgery. After the surgeon has removed all visible tumors, a heated chemotherapy solution (usually Cisplatin) is circulated inside the abdominal cavity for approximately ninety minutes while the patient is still under anesthesia.
The rationale is twofold: First, heat (hyperthermia) has a direct cytotoxic effect on cancer cells and impairs their ability to repair DNA damage. Second, the heat increases the penetration depth of the chemotherapy into the peritoneal tissues, targeting microscopic disease that the surgeon cannot see.
HIPEC is typically reserved for Stage III patients undergoing interval surgery after neoadjuvant chemotherapy. Clinical trials have demonstrated a survival advantage in this specific group. It is a significant procedure requiring careful physiological monitoring during the heating phase, but it represents a substantial advance in the locoregional control of the disease.
Beyond cytotoxic chemotherapy, biological therapies target specific pathways that tumors use to grow. Bevacizumab is a monoclonal antibody that targets Vascular Endothelial Growth Factor (VEGF). Ovarian tumors secrete VEGF to recruit new blood vessels (angiogenesis) to feed their rapid growth and to produce ascites.
By blocking VEGF, Bevacizumab starves the tumor of its blood supply and reduces vascular permeability, which significantly helps in controlling ascites. It is often added to the initial chemotherapy regimen and continued as “maintenance therapy” for about 15 months, particularly for patients with high-risk Stage III or Stage IV disease.
While Bevacizumab extends the time before the cancer comes back (progression-free survival), it carries specific risks, such as high blood pressure and rare but serious bowel perforations. Patient selection is careful, avoiding those with bowel involvement that might predispose them to perforation.
The most transformative development in ovarian cancer treatment has been the introduction of Poly (ADP-ribose) polymerase (PARP) inhibitors (e.g., Olaparib, Niraparib, Rucaparib). These oral drugs exploit a concept called “synthetic lethality.”
Cells have multiple ways to repair DNA. The BRCA genes repair double-strand breaks. PARP enzymes repair single-strand breaks. In cancer cells with a BRCA mutation (or Homologous Recombination Deficiency – HRD), the double-strand repair mechanism is already broken. If we then use a drug to block the PARP enzyme (which repairs single-strand breaks), the cancer cell has no way to repair its DNA, and it dies. Normal cells, which still have functioning BRCA genes, can survive the drug.
PARP inhibitors are now standard maintenance therapy for patients with BRCA mutations or HRD, taken for two to three years after chemotherapy ends. They have achieved unprecedentedly long remission times, offering the closest hope of a cure for advanced disease seen in decades. Even patients without mutations may derive some benefit, though the effect is strongest in the BRCA/HRD group.
Send us all your questions or requests, and our expert team will assist you.
Primary debulking is when surgery is the very first treatment, followed by chemotherapy. Interval debulking is when the patient gets 3-4 cycles of chemotherapy first to shrink the tumor, then has surgery, then gets more chemotherapy. The choice depends on how widespread the cancer is and the patient’s health.
HIPEC is not a standalone cure. It is an additional tool used during surgery to kill microscopic cells and reduce the chance of the cancer coming back in the abdomen. Studies show it improves survival in specific patient groups, but it is part of a larger treatment plan, not a magic bullet.
Since PARP inhibitors are taken daily as pills, side effects can be chronic. Common issues include fatigue, nausea, and anemia (low red blood cell count). Patients need regular blood tests to monitor their bone marrow function. Occasionally, they can increase the risk of rare blood disorders like leukemia.
With the standard Carboplatin and Paclitaxel regimen, total hair loss (alopecia) is expected. It usually starts 2-3 weeks after the first dose. However, the hair almost always grows back after chemotherapy is finished. Cold cap therapy may be an option for some to reduce hair loss, though success varies.
It depends. If the cancer is only on the surface of the liver, it can often be stripped off. If there are only a few small spots inside the liver, they might be removed (resected) or ablated. However, if the liver is full of cancer, surgery might not be beneficial, and systemic chemotherapy would be the primary treatment.
Many people are surprised to learn that lower back pain can signal ovarian cancer. This is true if the pain is new, keeps coming back,
Abdominal bloating and a visibly larger stomach are common signs of ovarian cancer. These symptoms are often mistaken for regular digestive issues. At Liv Hospital,
Many people think that ovarian cancer always leads to vaginal bleeding. But, the truth is more nuanced. We’re here to tell you that bleeding isn’t
Many women feel like they need to go to the bathroom all the time. But, it’s often because of ovarian cysts. These growths can make
Ovarian cancer is often called a ‘silent killer’ because its symptoms are not obvious and it’s often diagnosed late. Early detection is key to better
Ovarian cancer is a major threat to women’s health. Some groups face much higher risks because of their genes, family history, and lifestyle. It’s key
Leave your phone number and our medical team will call you back to discuss your healthcare needs and answer all your questions.
Your Comparison List (you must select at least 2 packages)
